0001326110-23-000106.txt : 20230828
0001326110-23-000106.hdr.sgml : 20230828
20230828205831
ACCESSION NUMBER: 0001326110-23-000106
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230825
FILED AS OF DATE: 20230828
DATE AS OF CHANGE: 20230828
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Sachs David C.
CENTRAL INDEX KEY: 0001848899
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37507
FILM NUMBER: 231217725
MAIL ADDRESS:
STREET 1: C/O IMMUNITYBIO, INC.
STREET 2: 3530 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ImmunityBio, Inc.
CENTRAL INDEX KEY: 0001326110
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 431979754
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3530 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: (844) 696-5235
MAIL ADDRESS:
STREET 1: 3530 JOHN HOPKINS COURT
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: NantKwest, Inc.
DATE OF NAME CHANGE: 20150713
FORMER COMPANY:
FORMER CONFORMED NAME: Conkwest, Inc.
DATE OF NAME CHANGE: 20140416
FORMER COMPANY:
FORMER CONFORMED NAME: ZelleRx Corp
DATE OF NAME CHANGE: 20050504
4
1
wk-form4_1693270702.xml
FORM 4
X0508
4
2023-08-25
0
0001326110
ImmunityBio, Inc.
IBRX
0001848899
Sachs David C.
C/O IMMUNITYBIO, INC.
3530 JOHN HOPKINS COURT
SAN DIEGO
CA
92121
0
1
0
0
Chief Financial Officer
0
Restricted Stock Units
2023-08-25
4
A
0
141489
0
A
Common Stock
141489
141489
D
Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, 70,744 of the RSUs subject to the award shall vest on September 1, 2023 and 70,745 of the RSUs subject to the award shall vest on January 31, 2024.
/s/ Jason Liljestrom, as Attorney-in-Fact
2023-08-28